Published in Lancet on January 05, 1991
Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A (1997) 2.04
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry (1999) 1.53
1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry (1997) 1.16
Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry (2000) 1.02
Magnetic resonance spectroscopy outcomes from a comprehensive magnetic resonance study of children with fetal alcohol spectrum disorders. Magn Reson Imaging (2009) 0.95
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol (2004) 0.82
1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry (1998) 0.80
Pathogenesis of multiple sclerosis: a blood-brain barrier disease. J R Soc Med (1992) 0.79
Proton magnetic resonance spectroscopy and multiple sclerosis. Lancet (1991) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Navigation-related structural change in the hippocampi of taxi drivers. Proc Natl Acad Sci U S A (2000) 8.17
Differential effects of early hippocampal pathology on episodic and semantic memory. Science (1997) 6.21
Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11
Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Observation of tissue metabolites using 31P nuclear magnetic resonance. Nature (1974) 4.13
Muscular fatigue investigated by phosphorus nuclear magnetic resonance. Nature (1978) 4.11
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Mapping of metabolites in whole animals by 31P NMR using surface coils. Nature (1980) 3.86
Mechanisms that contribute to the stable segregation of plasmids. Annu Rev Genet (1989) 3.75
Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study. Mol Biol Med (1983) 3.40
The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
Contraction and recovery of living muscles studies by 31P nuclear magnetic resonance. J Physiol (1977) 3.21
Partition of unit-copy miniplasmids to daughter cells. III. The DNA sequence and functional organization of the P1 partition region. J Mol Biol (1985) 3.21
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci (1993) 3.07
Examination of a case of suspected McArdle's syndrome by 31P nuclear magnetic resonance. N Engl J Med (1981) 3.00
Mechanical relaxation rate and metabolism studied in fatiguing muscle by phosphorus nuclear magnetic resonance. J Physiol (1980) 2.88
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Calculation difficulties in children of very low birthweight: a neural correlate. Brain (2001) 2.48
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The persistent vegetative state. BMJ (1995) 2.35
Management of acute optic neuritis. Lancet (2002) 2.33
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
Language reorganization in children with early-onset lesions of the left hemisphere: an fMRI study. Brain (2004) 2.22
Biochemical activities of the parA partition protein of the P1 plasmid. Mol Microbiol (1992) 2.19
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Magn Reson Med (2000) 2.17
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
The pattern-evoked potential in compression of the anterior visual pathways. Brain (1976) 2.07
The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05
Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem (1992) 2.05
Detection of hippocampal pathology in intractable partial epilepsy: increased sensitivity with quantitative magnetic resonance T2 relaxometry. Neurology (1993) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99
Distributional assumptions in voxel-based morphometry. Neuroimage (2002) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
MRI analysis of an inherited speech and language disorder: structural brain abnormalities. Brain (2002) 1.98
Magnetic resonance imaging findings within 5 days of status epilepticus in childhood. Brain (2002) 1.98
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Recognition of the P1 plasmid centromere analog involves binding of the ParB protein and is modified by a specific host factor. EMBO J (1988) 1.95
A rigorous framework for diffusion tensor calculus. Magn Reson Med (2005) 1.94
Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Energetics of human muscle: exercise-induced ATP depletion. Magn Reson Med (1986) 1.83
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Quantification of perfusion using bolus tracking magnetic resonance imaging in stroke: assumptions, limitations, and potential implications for clinical use. Stroke (2002) 1.81
Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry (2000) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
The P1 plasmid-partition system synthesizes two essential proteins from an autoregulated operon. Plasmid (1988) 1.80
Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80
Neural basis of an inherited speech and language disorder. Proc Natl Acad Sci U S A (1998) 1.76
NMR studies of tissue metabolism. Annu Rev Biochem (1981) 1.76
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
B-lymphocyte alloantigens associated with multiple sclerosis. Lancet (1976) 1.73
Neurological deterioration in young adults with phenylketonuria. Lancet (1990) 1.71
Pathophysiology of demyelinating disease. Br Med Bull (1977) 1.70